This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heimberger, A. B. Articles by Sampson, J. H. Search for Related Content PubMed PubMed Citation Articles by Heimberger, A. B. Articles by Sampson, J. H.

Temozolomide Delivered by Intracerebral Microinfusion is Safe and Efficacious Against Malignant Gliomas in Rats¹

Department of Surgery, Division of Neurosurgery [A. B. H., G. E. A., A. H. F., H. S. F., J. H. S.] and Department of Pathology [R. E. M., C. H., H. S. F., D. D. B., J. H. S.], Duke University Medical Center, Durham, North Carolina 27710

Intracerebral microinfusion (ICM) is an innovative technique of delivering therapeutic agents throughout large portions of the brain that circumvents the blood-brain barrier, minimizes systemic toxicity, and provides a homogeneous distribution of the infused agent. Temozolomide is a novel methylating agent with proven efficacy against malignant gliomas (MGs) after systemic administration but with dose-limiting myelotoxicity. Because MGs rarely metastasize, systemic drug delivery is unnecessary. Therefore, we evaluated the efficacy and toxicity of ICM with temozolomide in an athymic rat model of human MGs. Treatment of rats by ICM with temozolomide 3 days after intracerebral challenge with D54 human MG xenograft increased median survival by 128% compared with rats treated by ICM with saline, by 113% compared with rats treated with i.p. saline, and by 100% compared with rats treated with i.p. temozolomide (P < 0.001). Delay of treatment until 9 days after tumor challenge still resulted in a 23% increase in median survival in rats treated by ICM of temozolomide compared with rats treated with i.p. temozolomide. In addition, overall, 21.7% of rats treated by ICM with temozolomide survived for >100 days without clinical or histological evidence of tumor. The dose of temozolomide delivered by ICM in this study was limited only by drug solubility, and no neurological or systemic toxicity could be attributed to ICM with temozolomide. Therefore, ICM of temozolomide may offer significant advantages in the treatment of MGs.

This article has been cited by other articles:

				J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon II, S. Kunwar, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors Neuro-oncol, January 1, 2008; 10(3): 320 - 329. [Abstract] [Full Text] [PDF]

				j. H. Sampson, R. Raghavan, M. L. Brady, j. M. Provenzale, j. E. Herndon II, D. Croteau, A. H. Friedman, D. A. Reardon, R. E. Coleman, T. Wong, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions Neuro-oncol, July 1, 2007; 9(3): 343 - 353. [Abstract] [Full Text] [PDF]

				J. H. Sampson, R. Raghavan, J. M. Provenzale, D. Croteau, D. A. Reardon, R. E. Coleman, I. R. Ponce, I. Pastan, R. K. Puri, and C. Pedain Induction of Hyperintense Signal on T2-Weighted MR Images Correlates with Infusion Distribution from Intracerebral Convection-Enhanced Delivery of a Tumor-Targeted Cytotoxin Am. J. Roentgenol., March 1, 2007; 188(3): 703 - 709. [Abstract] [Full Text] [PDF]

				J. H. Sampson, D. A. Reardon, A. H. Friedman, H. S. Friedman, R. E. Coleman, R. E. McLendon, I. Pastan, and D. D. Bigner Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: Case study Neuro-oncol, January 1, 2005; 7(1): 90 - 96. [Abstract] [PDF]

				M. Vavra, M. J. Ali, E. W.-Y. Kang, Y. Navalitloha, A. Ebert, C. V. Allen, and D. R. Groothuis Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery Neuro-oncol, April 1, 2004; 6(2): 104 - 112. [Abstract] [PDF]

				N. O. Schmidt, M. Ziu, G. Carrabba, C. Giussani, L. Bello, Y. Sun, K. Schmidt, M. Albert, P. Mcl. Black, and R. S. Carroll Antiangiogenic Therapy by Local Intracerebral Microinfusion Improves Treatment Efficiency and Survival in an Orthotopic Human Glioblastoma Model Clin. Cancer Res., February 15, 2004; 10(4): 1255 - 1262. [Abstract] [Full Text] [PDF]

				P. M. Grossi, H. Ochiai, G. E. Archer, R. E. McLendon, M. R. Zalutsky, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson Efficacy of Intracerebral Microinfusion of Trastuzumab in an Athymic Rat Model of Intracerebral Metastatic Breast Cancer Clin. Cancer Res., November 15, 2003; 9(15): 5514 - 5520. [Abstract] [Full Text] [PDF]